Derleme
BibTex RIS Kaynak Göster

Uzamış Priapizmli Olgularda (>36 saat) Tedavi Yaklaşımları

Yıl 2018, Cilt: 10 Sayı: 4, 138 - 150, 01.09.2018

Fikret Erdemir Bekir Süha Parlaktaş Mete Kilciler

Öz

Priapizm cinsel uyarı olmaksızın penisin persiste ve uzamış ereksiyonu olarak tanımlanmaktadır. Bu bozukluğun patofizyolojisi hakkında sınırlı bilgilerimiz bulunmaktadır. İskemik ve noniskemik olmak üzere iki tip priapizm bulunmaktadır. Bu patolojide kavernozal hasar ve erektil disfonksiyonu önlemek için hızlı tedavi çok önemlidir. Bununla birlikte, uzamış (>36 saat) priapizmli olgularda tedavi yaklaşımları tartışmalıdır. Bu derlemede uzamış olgularda tedavi yaklaşımlarının fonksiyonel sonuçlara olan etkisi değerlendirildi.

Anahtar Kelimeler

Priapizm uzamış tedavi erektil disfonksiyon

Kaynakça

  • 1. Lue TF (1998) Physiology of penile erection and pathophysiology of erectile dysfunction and priapism. In: Walsh P, Retik AB, Vaughan ED, Wein AJ (eds) Campbell’s Urology, vol 3, 7th edn. Saunders Company, Philadelphia, pp 1157–1174
  • 2. Roghmann F, Becker A, Sammon JD, Ouerghi M, Sun M, Sukumar S, Djahangirian O, Zorn KC, Ghani KR, Gandaglia G, Menon M, Karakiewicz P, Noldus J, Trinh QD (2013) Incidence of priapism in emergency departments in the United States. J Urol 190:1275–1280
  • 3. Kadioglu A, Sanli O, Celtik M, Cakan M, Taskapu H, Akman T (2006) Practical management of patients with priapism. EAU-EBU Updat Ser 4:150–160
  • 4. Broderick GA, Kadioglu A, Bivalacqua TJ, Ghanem H, Nehra A, Shamloul R. Priapism: pathogenesis, epidemiology, and management. J Sex Med. 2010 Jan;7(1 Pt 2):476-500.
  • 5. Earle CM, Stuckey BG, Ching HL, Wisniewski ZS. The incidence and management of priapism in Western Australia: a 16 year audit. Int J Impot Res. 2003 Aug;15(4):272-6.
  • 6. Roghmann F1, Becker A, Sammon JD, Ouerghi M, Sun M, Sukumar S, Djahangirian O, Zorn KC, Ghani KR, Gandaglia G, Menon M, Karakiewicz P, Noldus J, Trinh QD. Incidence of priapism in emergency departments in the United States. J Urol. 2013 Oct;190(4):1275-80.
  • 7. Arduini GAO, Trovó de Marqui AB. Prevalence and Characteristics of Priapism in Sickle Cell Disease. Hemoglobin. 2018 Mar;42(2):73-77.
  • 8. Falcone M, Gillo A, Capece M, Raheem A, Ralph D, Garaffa G. The management of the acute ischemic priapism: A state of the art review. Actas Urol Esp. 2017 Dec;41(10):607-613.
  • 9. Shigehara K, Namiki M. Clinical Management of Priapism: A Review. World J Mens Health. 2016 Apr;34(1):1-8.
  • 10. Chinegwundoh FI, Smith S, Anie KA. Treatments for priapism in boys and men with sickle cell disease. Cochrane Database Syst Rev. 2017 Sep 19;9:CD004198. doi: 10.1002/14651858.CD004198.
  • 11. Ballas SK, Lyon D. Safety and efficacy of blood exchange transfusion for priapism complicating sickle cell disease. J Clin Apher. 2016 Feb;31(1):5-10.
  • 12. Olujohungbe A, Burnett AL. How I manage priapism due to sickle cell disease. Br J Haematol. 2013 Mar;160(6):754-65.
  • 13. Hatzimouratidis k. EAU Guidelines on Priapism. 2017.
  • 14. Erdemir F. Priapizm. Üroloji Akıl Notları.Güneş Tıp Kitabevleri.Editör: Emre Huri.2018;1. Basım, Ankara. 155-167.
  • 15. Gravel J, LeBlanc C, Varner C. Management of priapism with a trial of exercise in the emergency department. CJEM. 2019 Jan;21(1):150-153. d
  • 16. Ateyah A, Rahman El-Nashar A, Zohdy W, Arafa M, Saad El-Den H. Intracavernosal irrigation by cold saline as a simple method of treating iatrogenic prolonged erection. J Sex Med. 2005 Mar;2(2):248-53.
  • 17. Osmonov DK, Aksenov A, Guerra Sandoval AN, Kalz A, Juenemann KP. Barry shunt for treatment of a 76-hour stuttering priapism without subsequent erectile dysfunction. Res Rep Urol. 2014 Jul 23;6:91-5.
  • 18. Rees RW, Kalsi J, Minhas S, Peters J, Kell P, Ralph DJ. The management of low-flow priapism with the immediate insertion of a penile prosthesis. BJU Int. 2002 Dec;90(9):893-7.
  • 19. Kreitenberg AJ, Ortiz EC, Arkfeld DG. Priapism after tumor necrosis factor alpha inhibitor use. Clin Rheumatol. 2015 Apr;34(4):801-2.
  • 20. Coralic Z, Lenhoff T, Kanzaria HK, Gerona R. A 120-hour case of priapism from an over-the-counter herbal supplement. Ann Pharmacother. 2013 Feb;47(2):289-90.
  • 21. Singal R, Bawa AS, Singh R, Sahu P, Gupta A. Surgical management of resistant priapism. Indian J Surg. 2012 Dec;74(6):495-7.
  • 22. Segawa N, Takasaki N, Iwamoto Y, Hirai K, Katsuoka Y, Ueno N, Yasuda H. [Priapism treated by caverno-glandular shunt, caverno-saphenous shunt and caverno-spongiosum shunt: report of a case. Hinyokika Kiyo. 1998 Apr;44(4):297-300.
  • 23. Pivot D, Javot L, Swiegot D, Petitpain N, Spaëth D, Trechot P. Two cases of recurrent priapism during antineoplastic chemotherapy: think about ondansetron. Therapie. 2013 Nov-Dec;68(6):409-10.
  • 24. Clavijo RI, Sávio LF, Prakash NS, Masterson T, Eid JF, Ramasamy R. Three-piece Penile Prosthesis Implantation in Refractory Ischemic Priapism-Tips and Tricks. Urology. 2017 Aug;106:233-235.
  • 25. Asgari SA, Rostami S, Teimoori M. Leech Therapy for Treating Priapism: Case Report. Iran J Public Health. 2017 Jul;46(7):985-988.
  • 26. Afriansyah A, Yuri P, Hutasoit YI. Intracorporeal Dilatation Plus Al-Ghorab Corporoglandular Shunt for Salvage Management of Prolonged Ischemic Priapism. Urol Case Rep. 2017 Feb 20;12:11-13.
  • 27. Seideman CA, Gitlin JS. T-shaped Shunt With Intracavernosal Tunneling for a Pediatric Case of Refractory Ischemic Priapism. Urology. 2017 Dec;110:220-222.
  • 28. Kalathia J, Agrawal S, Chipde SS, Agrawal R. Homocysteinemia: A rare cause of priapism. Urol Ann. 2016 Jan-Mar;8(1):118-21.
  • 29. Muneer A, Minhas S, Freeman A, Kumar P, Ralph DJ. Investigating the effects of high-dose phenylephrine in the management of prolonged ischaemic priapism. J Sex Med. 2008 Sep;5(9):2152-9.
  • 30. Bondil P, Descottes JL, Salti A, Sabbagh R, Hamza T. [Medical treatment of venous priapism apropos of 46 cases: puncture, pharmacologic detumescence or penile cooling? Prog Urol. 1997 Jun;7(3):433-41.
  • 31. Bennett N, Mulhall J. Sickle cell disease status and outcomes of African-American men presenting with priapism. J Sex Med. 2008 May;5(5):1244-1250.
  • 32. Kulmala RV, Tamella TL. Effects of priapism lasting 24 hours or longer caused by intracavernosal injection of vasoactive drugs. Int J Impot Res. 1995 Jun;7(2):131-6.
  • 33. Salabaş E, Kadıoğlu A. Priapizm Tedavisinde Şant Teknikleri Değişti mi? Priapizm Tedavisinde Şant Teknikleri Değişti mi?
  • 34. Müller A. al-Ghorab Shunt for Priapism. J Sex Med. 2016 Aug;13(8):1279-84.
  • 35. Shiraishi K, Matsuyama H. Salvage management of prolonged ischemic priapism: Al-Ghorab shunt plus cavernous tunneling with blunt cavernosotomy. J Sex Med. 2013 Feb;10(2):599-602. d
  • 36. Segal RL, Readal N, Pierorazio PM, Burnett AL, Bivalacqua TJ. Corporal Burnett "Snake" surgical maneuver for the treatment of ischemic priapism: long-term followup. J Urol. 2013 Mar;189(3):1025-9.
  • 37. Lue TF, Pescatori ES. Distal cavernosum-glans shunts for ischemic priapism. J Sex Med. 2006 Jul;3(4):749-752.
  • 38. Sönmez MG, Öztürk Sönmez L, Taşkapu HH, Kara C, Dündar ZD, Göğer YE, Evrin T, Öztürk A. Etiological factors and management in priapism patients and attitude of emergency physicians. Arch Ital Urol Androl. 2017 Oct 3;89(3):203-207.
  • 39. Earle CM, Stuckey BG, Ching HL, Wisniewski ZS. The incidence and management of priapism in Western Australia: a 16 year audit. Int J Impot Res. 2003 Aug;15(4):272-6.
  • 40. Ahmed M, Augustine B, Matthew M, Awaisu M, Sudi A, Hamza KB, Bello A, Maitama HY. Prognostic Factors and Outcome of Management of Ischemic Priapism in Zaria, Nigeria. Niger J Surg. 2017 Jan-Jun;23(1):15-19.
  • 41. Zheng DC, Yao HJ, Zhang K, Xu MX, Chen Q, Chen YB, Cai ZK, Lu MJ, Wang Z. Unsatisfactory outcomes of prolonged ischemic priapism without early surgical shunts: our clinical experience and a review of the literature. Asian J Androl. 2013 Jan;15(1):75-8. d
  • 42. Pal DK, Biswal DK, Ghosh B. Outcome and erectile function following treatment of priapism: An institutional experience. Urol Ann. 2016 Jan-Mar;8(1):46-50.
  • 43. Garcia MM, Shindel AW, Lue TF. T-shunt with or without tunnelling for prolonged ischaemic priapism. BJU Int. 2008 Dec;102(11):1754-64.
  • 44. Kaisary AV, Smith PJ. Aetiological factors and management of priapism in Bristol 1978-1983. Ann R Coll Surg Engl. 1986 Sep;68(5):252-4.
  • 45. Ugwumba FO1, Ekwedigwe HC, Echetabu KN, Okoh AD, Nnabugwu I, Ugwuidu ES. Ischemic priapism in South-East Nigeria: Presentation, management challenges, and aftermath issues.
  • 46. Zhang GX, Bai WJ, Li Q, Wang XF. [Distal cavernosal-glan shunt for ischemic priapism: a long-term follow-up study. Zhonghua Nan Ke Xue. 2013 Nov;19(11):988-90.
  • 47. Lian W, Lv J, Cui W, Jin Z, Liu T, Li W, Yuan Y, Xin Z. Al-Ghorab Shunt plus intracavernous tunneling for prolonged ischemic priapism. J Androl. 2010 Sep-Oct;31(5):466-71.
  • 48. Brant WO, Garcia MM, Bella AJ, Chi T, Lue TF. T-shaped shunt and intracavernous tunneling for prolonged ischemic priapism. J Urol. 2009 Apr;181(4):1699-705.
  • 49. Burnett AL, Pierorazio PM. Corporal "snake" maneuver: corporoglanular shunt surgical modification for ischemic priapism. J Sex Med. 2009 Apr;6(4):1171-1176.
  • 50. Shiraishi K, Matsuyama H. Salvage management of prolonged ischemic priapism: Al-Ghorab shunt plus cavernous tunneling with blunt cavernosotomy. J Sex Med. 2013 Feb;10(2):599-602.
  • 51. Moore J, Whelan TF, Langille GM. The use of penile prostheses in the management of priapism. Transl Androl Urol. 2017 Nov;6(Suppl 5):S797-S803. doi: 10.21037/tau.2017.04.26.
  • 52. Capece M, La Rocca R, Mirone V, Bivalacqua TJ, Castiglione F, Albersen M, Ralph DJ, Muneer A, Garaffa G. A Systematic Review on Ischemic Priapism and Immediate Implantation: Do We Need More Data? Sex Med Rev. 2019 Jul;7(3):530-534.
  • 53. Sedigh O, Rolle L, Negro CL, Ceruti C, Timpano M, Galletto E, Soltanzadeh K, Ajamy H, Hosseinee J, Al Ansari A, Shamsodini A, Fontana D. Early insertion of inflatable prosthesis for intractable ischemic priapism: our experience and review of the literature. Int J Impot Res. 2011 Jul-Aug;23(4):158-64.
  • 54. Ralph DJ, Borley NC, Allen C, Kirkham A, Freeman A, Minhas S, Muneer A. The use of high-resolution magnetic resonance imaging in the management of patients presenting with priapism. BJU Int. 2010 Dec;106(11):1714-8.
  • 55. Muneer A, Ralph DJ. Immediate Placement of a Penile Prosthesis as First-line Treatment for the Management of Ischaemic Priapism. Eur Urol Focus. 2019 Jul;5(4):529-530.
  • 56. Zacharakis E, Garaffa G, Raheem AA, Christopher AN, Muneer A, Ralph DJ. Penile prosthesis insertion in patients with refractory ischaemic priapism: early vs delayed implantation. BJU Int. 2014 Oct;114(4):576-81.
  • 57. Kumar M, Garg G, Sharma A, Pandey S, Singh M, Sankhwar SN. Comparison of outcomes in malignant vs. non-malignant ischemic priapism: 12-year experience from a tertiary center. Turk J Urol. 2019 Feb 20;45(5):340-344.
  • 58. De Luca F, Zacharakis E, Shabbir M, Maurizi A, Manzi E, Zanghì A, De Dominicis C, Ralph D. Malignant priapism due to penile metastases: Case series and literature review. Arch Ital Urol Androl. 2016 Jul 4;88(2):150-2.

Treatment Approaches in Patients with Prolonged Priapism (>36 hours)

Yıl 2018, Cilt: 10 Sayı: 4, 138 - 150, 01.09.2018

Fikret Erdemir Bekir Süha Parlaktaş Mete Kilciler

Öz

Priapism is defined as prolonged and persistent erection of the penis without sexual stimulation. We have limited information on the pathophysiology of this disorder. Two main types of priapism exist: ischemic and nonischemic priapism. In this pathology, prompt treatment is very important to prevent of cavernosal damage and erectile dysfunction. However, treatment approaches and treatment results are controversial in patients with prolonged (>36 hours) priapism. In this review the effect of treatment approaches on functional results were evaluated in prolonged patients.

Anahtar Kelimeler

Priapism prolonged treatment erectile dysfunction

Kaynakça

  • 1. Lue TF (1998) Physiology of penile erection and pathophysiology of erectile dysfunction and priapism. In: Walsh P, Retik AB, Vaughan ED, Wein AJ (eds) Campbell’s Urology, vol 3, 7th edn. Saunders Company, Philadelphia, pp 1157–1174
  • 2. Roghmann F, Becker A, Sammon JD, Ouerghi M, Sun M, Sukumar S, Djahangirian O, Zorn KC, Ghani KR, Gandaglia G, Menon M, Karakiewicz P, Noldus J, Trinh QD (2013) Incidence of priapism in emergency departments in the United States. J Urol 190:1275–1280
  • 3. Kadioglu A, Sanli O, Celtik M, Cakan M, Taskapu H, Akman T (2006) Practical management of patients with priapism. EAU-EBU Updat Ser 4:150–160
  • 4. Broderick GA, Kadioglu A, Bivalacqua TJ, Ghanem H, Nehra A, Shamloul R. Priapism: pathogenesis, epidemiology, and management. J Sex Med. 2010 Jan;7(1 Pt 2):476-500.
  • 5. Earle CM, Stuckey BG, Ching HL, Wisniewski ZS. The incidence and management of priapism in Western Australia: a 16 year audit. Int J Impot Res. 2003 Aug;15(4):272-6.
  • 6. Roghmann F1, Becker A, Sammon JD, Ouerghi M, Sun M, Sukumar S, Djahangirian O, Zorn KC, Ghani KR, Gandaglia G, Menon M, Karakiewicz P, Noldus J, Trinh QD. Incidence of priapism in emergency departments in the United States. J Urol. 2013 Oct;190(4):1275-80.
  • 7. Arduini GAO, Trovó de Marqui AB. Prevalence and Characteristics of Priapism in Sickle Cell Disease. Hemoglobin. 2018 Mar;42(2):73-77.
  • 8. Falcone M, Gillo A, Capece M, Raheem A, Ralph D, Garaffa G. The management of the acute ischemic priapism: A state of the art review. Actas Urol Esp. 2017 Dec;41(10):607-613.
  • 9. Shigehara K, Namiki M. Clinical Management of Priapism: A Review. World J Mens Health. 2016 Apr;34(1):1-8.
  • 10. Chinegwundoh FI, Smith S, Anie KA. Treatments for priapism in boys and men with sickle cell disease. Cochrane Database Syst Rev. 2017 Sep 19;9:CD004198. doi: 10.1002/14651858.CD004198.
  • 11. Ballas SK, Lyon D. Safety and efficacy of blood exchange transfusion for priapism complicating sickle cell disease. J Clin Apher. 2016 Feb;31(1):5-10.
  • 12. Olujohungbe A, Burnett AL. How I manage priapism due to sickle cell disease. Br J Haematol. 2013 Mar;160(6):754-65.
  • 13. Hatzimouratidis k. EAU Guidelines on Priapism. 2017.
  • 14. Erdemir F. Priapizm. Üroloji Akıl Notları.Güneş Tıp Kitabevleri.Editör: Emre Huri.2018;1. Basım, Ankara. 155-167.
  • 15. Gravel J, LeBlanc C, Varner C. Management of priapism with a trial of exercise in the emergency department. CJEM. 2019 Jan;21(1):150-153. d
  • 16. Ateyah A, Rahman El-Nashar A, Zohdy W, Arafa M, Saad El-Den H. Intracavernosal irrigation by cold saline as a simple method of treating iatrogenic prolonged erection. J Sex Med. 2005 Mar;2(2):248-53.
  • 17. Osmonov DK, Aksenov A, Guerra Sandoval AN, Kalz A, Juenemann KP. Barry shunt for treatment of a 76-hour stuttering priapism without subsequent erectile dysfunction. Res Rep Urol. 2014 Jul 23;6:91-5.
  • 18. Rees RW, Kalsi J, Minhas S, Peters J, Kell P, Ralph DJ. The management of low-flow priapism with the immediate insertion of a penile prosthesis. BJU Int. 2002 Dec;90(9):893-7.
  • 19. Kreitenberg AJ, Ortiz EC, Arkfeld DG. Priapism after tumor necrosis factor alpha inhibitor use. Clin Rheumatol. 2015 Apr;34(4):801-2.
  • 20. Coralic Z, Lenhoff T, Kanzaria HK, Gerona R. A 120-hour case of priapism from an over-the-counter herbal supplement. Ann Pharmacother. 2013 Feb;47(2):289-90.
  • 21. Singal R, Bawa AS, Singh R, Sahu P, Gupta A. Surgical management of resistant priapism. Indian J Surg. 2012 Dec;74(6):495-7.
  • 22. Segawa N, Takasaki N, Iwamoto Y, Hirai K, Katsuoka Y, Ueno N, Yasuda H. [Priapism treated by caverno-glandular shunt, caverno-saphenous shunt and caverno-spongiosum shunt: report of a case. Hinyokika Kiyo. 1998 Apr;44(4):297-300.
  • 23. Pivot D, Javot L, Swiegot D, Petitpain N, Spaëth D, Trechot P. Two cases of recurrent priapism during antineoplastic chemotherapy: think about ondansetron. Therapie. 2013 Nov-Dec;68(6):409-10.
  • 24. Clavijo RI, Sávio LF, Prakash NS, Masterson T, Eid JF, Ramasamy R. Three-piece Penile Prosthesis Implantation in Refractory Ischemic Priapism-Tips and Tricks. Urology. 2017 Aug;106:233-235.
  • 25. Asgari SA, Rostami S, Teimoori M. Leech Therapy for Treating Priapism: Case Report. Iran J Public Health. 2017 Jul;46(7):985-988.
  • 26. Afriansyah A, Yuri P, Hutasoit YI. Intracorporeal Dilatation Plus Al-Ghorab Corporoglandular Shunt for Salvage Management of Prolonged Ischemic Priapism. Urol Case Rep. 2017 Feb 20;12:11-13.
  • 27. Seideman CA, Gitlin JS. T-shaped Shunt With Intracavernosal Tunneling for a Pediatric Case of Refractory Ischemic Priapism. Urology. 2017 Dec;110:220-222.
  • 28. Kalathia J, Agrawal S, Chipde SS, Agrawal R. Homocysteinemia: A rare cause of priapism. Urol Ann. 2016 Jan-Mar;8(1):118-21.
  • 29. Muneer A, Minhas S, Freeman A, Kumar P, Ralph DJ. Investigating the effects of high-dose phenylephrine in the management of prolonged ischaemic priapism. J Sex Med. 2008 Sep;5(9):2152-9.
  • 30. Bondil P, Descottes JL, Salti A, Sabbagh R, Hamza T. [Medical treatment of venous priapism apropos of 46 cases: puncture, pharmacologic detumescence or penile cooling? Prog Urol. 1997 Jun;7(3):433-41.
  • 31. Bennett N, Mulhall J. Sickle cell disease status and outcomes of African-American men presenting with priapism. J Sex Med. 2008 May;5(5):1244-1250.
  • 32. Kulmala RV, Tamella TL. Effects of priapism lasting 24 hours or longer caused by intracavernosal injection of vasoactive drugs. Int J Impot Res. 1995 Jun;7(2):131-6.
  • 33. Salabaş E, Kadıoğlu A. Priapizm Tedavisinde Şant Teknikleri Değişti mi? Priapizm Tedavisinde Şant Teknikleri Değişti mi?
  • 34. Müller A. al-Ghorab Shunt for Priapism. J Sex Med. 2016 Aug;13(8):1279-84.
  • 35. Shiraishi K, Matsuyama H. Salvage management of prolonged ischemic priapism: Al-Ghorab shunt plus cavernous tunneling with blunt cavernosotomy. J Sex Med. 2013 Feb;10(2):599-602. d
  • 36. Segal RL, Readal N, Pierorazio PM, Burnett AL, Bivalacqua TJ. Corporal Burnett "Snake" surgical maneuver for the treatment of ischemic priapism: long-term followup. J Urol. 2013 Mar;189(3):1025-9.
  • 37. Lue TF, Pescatori ES. Distal cavernosum-glans shunts for ischemic priapism. J Sex Med. 2006 Jul;3(4):749-752.
  • 38. Sönmez MG, Öztürk Sönmez L, Taşkapu HH, Kara C, Dündar ZD, Göğer YE, Evrin T, Öztürk A. Etiological factors and management in priapism patients and attitude of emergency physicians. Arch Ital Urol Androl. 2017 Oct 3;89(3):203-207.
  • 39. Earle CM, Stuckey BG, Ching HL, Wisniewski ZS. The incidence and management of priapism in Western Australia: a 16 year audit. Int J Impot Res. 2003 Aug;15(4):272-6.
  • 40. Ahmed M, Augustine B, Matthew M, Awaisu M, Sudi A, Hamza KB, Bello A, Maitama HY. Prognostic Factors and Outcome of Management of Ischemic Priapism in Zaria, Nigeria. Niger J Surg. 2017 Jan-Jun;23(1):15-19.
  • 41. Zheng DC, Yao HJ, Zhang K, Xu MX, Chen Q, Chen YB, Cai ZK, Lu MJ, Wang Z. Unsatisfactory outcomes of prolonged ischemic priapism without early surgical shunts: our clinical experience and a review of the literature. Asian J Androl. 2013 Jan;15(1):75-8. d
  • 42. Pal DK, Biswal DK, Ghosh B. Outcome and erectile function following treatment of priapism: An institutional experience. Urol Ann. 2016 Jan-Mar;8(1):46-50.
  • 43. Garcia MM, Shindel AW, Lue TF. T-shunt with or without tunnelling for prolonged ischaemic priapism. BJU Int. 2008 Dec;102(11):1754-64.
  • 44. Kaisary AV, Smith PJ. Aetiological factors and management of priapism in Bristol 1978-1983. Ann R Coll Surg Engl. 1986 Sep;68(5):252-4.
  • 45. Ugwumba FO1, Ekwedigwe HC, Echetabu KN, Okoh AD, Nnabugwu I, Ugwuidu ES. Ischemic priapism in South-East Nigeria: Presentation, management challenges, and aftermath issues.
  • 46. Zhang GX, Bai WJ, Li Q, Wang XF. [Distal cavernosal-glan shunt for ischemic priapism: a long-term follow-up study. Zhonghua Nan Ke Xue. 2013 Nov;19(11):988-90.
  • 47. Lian W, Lv J, Cui W, Jin Z, Liu T, Li W, Yuan Y, Xin Z. Al-Ghorab Shunt plus intracavernous tunneling for prolonged ischemic priapism. J Androl. 2010 Sep-Oct;31(5):466-71.
  • 48. Brant WO, Garcia MM, Bella AJ, Chi T, Lue TF. T-shaped shunt and intracavernous tunneling for prolonged ischemic priapism. J Urol. 2009 Apr;181(4):1699-705.
  • 49. Burnett AL, Pierorazio PM. Corporal "snake" maneuver: corporoglanular shunt surgical modification for ischemic priapism. J Sex Med. 2009 Apr;6(4):1171-1176.
  • 50. Shiraishi K, Matsuyama H. Salvage management of prolonged ischemic priapism: Al-Ghorab shunt plus cavernous tunneling with blunt cavernosotomy. J Sex Med. 2013 Feb;10(2):599-602.
  • 51. Moore J, Whelan TF, Langille GM. The use of penile prostheses in the management of priapism. Transl Androl Urol. 2017 Nov;6(Suppl 5):S797-S803. doi: 10.21037/tau.2017.04.26.
  • 52. Capece M, La Rocca R, Mirone V, Bivalacqua TJ, Castiglione F, Albersen M, Ralph DJ, Muneer A, Garaffa G. A Systematic Review on Ischemic Priapism and Immediate Implantation: Do We Need More Data? Sex Med Rev. 2019 Jul;7(3):530-534.
  • 53. Sedigh O, Rolle L, Negro CL, Ceruti C, Timpano M, Galletto E, Soltanzadeh K, Ajamy H, Hosseinee J, Al Ansari A, Shamsodini A, Fontana D. Early insertion of inflatable prosthesis for intractable ischemic priapism: our experience and review of the literature. Int J Impot Res. 2011 Jul-Aug;23(4):158-64.
  • 54. Ralph DJ, Borley NC, Allen C, Kirkham A, Freeman A, Minhas S, Muneer A. The use of high-resolution magnetic resonance imaging in the management of patients presenting with priapism. BJU Int. 2010 Dec;106(11):1714-8.
  • 55. Muneer A, Ralph DJ. Immediate Placement of a Penile Prosthesis as First-line Treatment for the Management of Ischaemic Priapism. Eur Urol Focus. 2019 Jul;5(4):529-530.
  • 56. Zacharakis E, Garaffa G, Raheem AA, Christopher AN, Muneer A, Ralph DJ. Penile prosthesis insertion in patients with refractory ischaemic priapism: early vs delayed implantation. BJU Int. 2014 Oct;114(4):576-81.
  • 57. Kumar M, Garg G, Sharma A, Pandey S, Singh M, Sankhwar SN. Comparison of outcomes in malignant vs. non-malignant ischemic priapism: 12-year experience from a tertiary center. Turk J Urol. 2019 Feb 20;45(5):340-344.
  • 58. De Luca F, Zacharakis E, Shabbir M, Maurizi A, Manzi E, Zanghì A, De Dominicis C, Ralph D. Malignant priapism due to penile metastases: Case series and literature review. Arch Ital Urol Androl. 2016 Jul 4;88(2):150-2.
Toplam 58 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Konular Klinik Tıp Bilimleri
Bölüm Derleme
Yazarlar

Fikret Erdemir

Bekir Süha Parlaktaş Bu kişi benim

Mete Kilciler Bu kişi benim

Yayımlanma Tarihi 1 Eylül 2018
Yayımlandığı Sayı Yıl 2018 Cilt: 10 Sayı: 4

Kaynak Göster

APA Erdemir, F., Parlaktaş, B. S., & Kilciler, M. (2018). Uzamış Priapizmli Olgularda (>36 saat) Tedavi Yaklaşımları. Gaziosmanpaşa Üniversitesi Tıp Fakültesi Dergisi, 10(4), 138-150.
AMA Erdemir F, Parlaktaş BS, Kilciler M. Uzamış Priapizmli Olgularda (>36 saat) Tedavi Yaklaşımları. Gaziosmanpaşa Tıp Dergisi. Eylül 2018;10(4):138-150.
Chicago Erdemir, Fikret, Bekir Süha Parlaktaş, ve Mete Kilciler. “Uzamış Priapizmli Olgularda (>36 Saat) Tedavi Yaklaşımları”. Gaziosmanpaşa Üniversitesi Tıp Fakültesi Dergisi 10, sy. 4 (Eylül 2018): 138-50.
EndNote Erdemir F, Parlaktaş BS, Kilciler M (01 Eylül 2018) Uzamış Priapizmli Olgularda (>36 saat) Tedavi Yaklaşımları. Gaziosmanpaşa Üniversitesi Tıp Fakültesi Dergisi 10 4 138–150.
IEEE F. Erdemir, B. S. Parlaktaş, ve M. Kilciler, “Uzamış Priapizmli Olgularda (>36 saat) Tedavi Yaklaşımları”, Gaziosmanpaşa Tıp Dergisi, c. 10, sy. 4, ss. 138–150, 2018.
ISNAD Erdemir, Fikret vd. “Uzamış Priapizmli Olgularda (>36 Saat) Tedavi Yaklaşımları”. Gaziosmanpaşa Üniversitesi Tıp Fakültesi Dergisi 10/4 (Eylül 2018), 138-150.
JAMA Erdemir F, Parlaktaş BS, Kilciler M. Uzamış Priapizmli Olgularda (>36 saat) Tedavi Yaklaşımları. Gaziosmanpaşa Tıp Dergisi. 2018;10:138–150.
MLA Erdemir, Fikret vd. “Uzamış Priapizmli Olgularda (>36 Saat) Tedavi Yaklaşımları”. Gaziosmanpaşa Üniversitesi Tıp Fakültesi Dergisi, c. 10, sy. 4, 2018, ss. 138-50.
Vancouver Erdemir F, Parlaktaş BS, Kilciler M. Uzamış Priapizmli Olgularda (>36 saat) Tedavi Yaklaşımları. Gaziosmanpaşa Tıp Dergisi. 2018;10(4):138-50.

-